Hanmi Pharm KRX:128940KOSPI

한미약품 · Korean news coverage and regulatory filings, organized.

Articles, 24h42
Articles, 7 days48
DART filings, 7 days3
Articles tracked48since Sep 11

In Q2 2026, Hanmi Pharm reported revenue of ₩467bn, up 29.3% year on year, and operating profit of ₩131bn. Hanmi Pharm (한미약품) appeared in 48 Korean news articles and 3 DART filings over the past seven days. Coverage peaked on Sep 14 with 42 articles. The most common catalyst was tech & capacity (1). It was most often mentioned alongside Celltrion, Samsung Biologics and ST Pharm.

Hanmi Pharm quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩467bn+29.3%₩131bn₩84.1bn
Q1 2026₩393bn+0.5%₩53.6bn₩51.1bn
Q4 2025 derived₩433bn+23.1%₩83.3bn₩54.1bn
Q3 2025₩362bn+0.1%₩55.1bn₩45.4bn
Q2 2025₩361bn-4.5%₩60.4bn₩43.0bn
Q1 2025₩391bn-3.2%₩59.0bn₩44.7bn
Q4 2024 derived₩352bn-16.7%₩30.5bn−₩4.8bn
Q3 2024₩362bn-0.7%₩51.0bn₩35.0bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.

Hanmi Pharm top stories 2 weeks, by number of outlets

  1. 1
  2. 2
    '앤'이 누구야? 한미약품, 일반약 '앤 시리즈' 통합 캐릭터 만든다
    4 outlets · 4 articlesFirst report Sep 14 13:56 파이낸셜뉴스
  3. 3
    한미약품, ‘OO앤’ 시리즈에 캐릭터 ‘앤’ 입힌다
    4 outlets · 4 articlesFirst report Sep 14 14:50 스마트투데이
  4. 4
  5. 5
    한미약품, 일반약 앤 시리즈 공식 캐릭터 '앤' 선보여
    2 outlets · 2 articlesFirst report Sep 14 14:14 아시아경제
  6. 6

Latest Hanmi Pharm news Korean headlines